Meridian Acquires Euprotein to Further Expand Recombinant Protein Capabilities

Meridian Bioscience, Inc. (Cincinnati, OH, USA) has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. (North Brunswick Township, NJ, USA).

EUPROTEIN offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  The acquisition will help Meridian accelerate its pipeline of new immunological reagents while expanding recombinant capabilities.

"We are excited to welcome EUPROTEIN into the Meridian family," said Jack Kenny, Meridian Bioscience Chief Executive Officer.  "We already extensively work with EUPROTEIN on projects with our Life Science R&D team, and they are well-positioned to help us accelerate our pipeline of new immunological reagents."

"The EUPROTEIN team is delighted to join Meridian," added Guangli Wang, Ph.D., Founder, and CEO of EUPROTEIN. "Combining our products and capabilities with Meridian's global reach and stellar reputation for providing the highest quality reagents furthers our vision of making a lasting impact on global healthcare."

Related Links:
Meridian Bioscience, Inc. 
EUPROTEIN Inc.